Efficacy and preservation of hearing with low-dose gentamicin in unilateral meniere's disease : A clinical symptomatology-based study
Copyright © 2023 Elsevier Inc. All rights reserved..
PURPOSE: Meniere's disease (MD), a disorder of the inner ear, presents numerous therapeutic challenges, and intratympanic (IT) gentamicin has been proposed for intractable cases. However, controversy regarding dosage and method persists. The purpose of this study was to assess the efficacy and safety of low-dose IT gentamicin on vertigo attacks in MD using a clinical symptomatology-based method, wherein administration was repeated only if vertigo attacks recurred, with a 2-week interval between injections.
MATERIALS AND METHODS: This study included 88 patients with unilateral intractable MD. All patients received one to five IT injections with 0.5 ml of 10 mg of gentamicin (80 mg/2 ml) with an interval of 2 weeks between injections. Vertigo attacks were evaluated before and after therapy and categorized into classes A-F according to the 2015 Equilibrium Committee criteria. Audiovestibular assessments, including Pure Tone Audiometry and Vestibulo-Ocular Reflex evaluations, were performed.
RESULTS: Before treatment, patients had an average of 4.4 vertigo attacks/month; after treatment, this average decreased to 0.52. The majority of patients (57 %) reached Class A or B vertigo control with five or fewer gentamicin injections. VOR gain was slightly affected on the healthy side and significantly reduced on the affected side. No hearing deterioration was found in any of the treated patients.
CONCLUSIONS: Low-dose IT gentamicin administration based on clinical symptomatology can produce a satisfactory control of vertigo attacks after treatment. This protocol primarily affected the vestibular function, as demonstrated by the significant reduction in VOR gain on the affected side, while avoiding cochlear damage. The lack of adverse events and preservation of hearing underscore the safety and efficacy of this method. These findings have significant clinical implications, suggesting that a low-dose, clinical symptomatology-based gentamicin treatment regimen could be an effective and safe strategy for managing unilateral Meniere's disease in a larger population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
American journal of otolaryngology - 45(2023), 1 vom: 01. Jan., Seite 104116 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Scarpa, Alfonso [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 16.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.amjoto.2023.104116 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364754486 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364754486 | ||
| 003 | DE-627 | ||
| 005 | 20231227133740.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.amjoto.2023.104116 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1231.xml |
| 035 | |a (DE-627)NLM364754486 | ||
| 035 | |a (NLM)37984050 | ||
| 035 | |a (PII)S0196-0709(23)00330-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Scarpa, Alfonso |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and preservation of hearing with low-dose gentamicin in unilateral meniere's disease |b A clinical symptomatology-based study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 16.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a PURPOSE: Meniere's disease (MD), a disorder of the inner ear, presents numerous therapeutic challenges, and intratympanic (IT) gentamicin has been proposed for intractable cases. However, controversy regarding dosage and method persists. The purpose of this study was to assess the efficacy and safety of low-dose IT gentamicin on vertigo attacks in MD using a clinical symptomatology-based method, wherein administration was repeated only if vertigo attacks recurred, with a 2-week interval between injections | ||
| 520 | |a MATERIALS AND METHODS: This study included 88 patients with unilateral intractable MD. All patients received one to five IT injections with 0.5 ml of 10 mg of gentamicin (80 mg/2 ml) with an interval of 2 weeks between injections. Vertigo attacks were evaluated before and after therapy and categorized into classes A-F according to the 2015 Equilibrium Committee criteria. Audiovestibular assessments, including Pure Tone Audiometry and Vestibulo-Ocular Reflex evaluations, were performed | ||
| 520 | |a RESULTS: Before treatment, patients had an average of 4.4 vertigo attacks/month; after treatment, this average decreased to 0.52. The majority of patients (57 %) reached Class A or B vertigo control with five or fewer gentamicin injections. VOR gain was slightly affected on the healthy side and significantly reduced on the affected side. No hearing deterioration was found in any of the treated patients | ||
| 520 | |a CONCLUSIONS: Low-dose IT gentamicin administration based on clinical symptomatology can produce a satisfactory control of vertigo attacks after treatment. This protocol primarily affected the vestibular function, as demonstrated by the significant reduction in VOR gain on the affected side, while avoiding cochlear damage. The lack of adverse events and preservation of hearing underscore the safety and efficacy of this method. These findings have significant clinical implications, suggesting that a low-dose, clinical symptomatology-based gentamicin treatment regimen could be an effective and safe strategy for managing unilateral Meniere's disease in a larger population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Hearing preservation | |
| 650 | 4 | |a Intratympanic gentamicin | |
| 650 | 4 | |a Meniere disease | |
| 650 | 4 | |a Vertigo control | |
| 650 | 7 | |a Gentamicins |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Avallone, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Carucci, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Salzano, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Chiarella, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Cassandro, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Viola, Pasquale |e verfasserin |4 aut | |
| 700 | 1 | |a Ricciardiello, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Ralli, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a De Luca, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Salzano, Francesco Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of otolaryngology |d 1993 |g 45(2023), 1 vom: 01. Jan., Seite 104116 |w (DE-627)NLM000961876 |x 1532-818X |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:104116 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.amjoto.2023.104116 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2023 |e 1 |b 01 |c 01 |h 104116 | ||